Sift Biosciences Announces Oversubscribed $3.7M Pre-seed Financing to Advance Next-generation T-cell Immunotherapy Platform
Sift Biosciences, a UC Berkeley spinout developing a next-generation peptide immunotherapy platform that integrates AI, metagenomics, and high-throughput immune profiling, today announced the closing of a $3.7M Pre-Seed financing, co-led by Freeflow Ventures and Lifespan Vision Ventures, with participation from Valuence Ventures, Eisai Innovation, SBI US Gateway Fund and other early supporters.
